Lantheus Holdings (LNTH) Return on Capital Employed (2015 - 2026)
Lantheus Holdings (LNTH) posted quarterly Return on Capital Employed of 14.85% for Q1 2026, down 1072.0% year-over-year from 1.53% in Q1 2025, and down 8.36% quarter-over-quarter from 16.2% in Q4 2025.
Lantheus Holdings (LNTH) Return on Capital Employed (2015 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has reported Return on Capital Employed for 12 consecutive years, with 14.85% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 1072.0% year-over-year to 14.85%; the TTM figure through Mar 2026 stood at 14.85% (down 1072.0% YoY), while the FY2025 annual figure was 17.56%, down 1145.0% from the prior year.
- Return on Capital Employed declined to 14.85% in Q1 2026 per LNTH's latest filing, from 16.2% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 39.7% in Q3 2024 and bottomed at 3.03% in Q1 2023.
- Historically, Return on Capital Employed has averaged 16.9% across 5 years, with a median of 18.79% in 2025.
- Annual changes were most pronounced in 2024 — Return on Capital Employed jumped 3527 bps — and 2025, when it tumbled 2091 bps.
- Lantheus Holdings' Return on Capital Employed stood at 3.77% in 2022, then surged by 592 bps to 26.06% in 2023, then decreased by 1 bps to 25.75% in 2024, then slumped by 37 bps to 16.2% in 2025, then fell by 8 bps to 14.85% in 2026.
- Business Quant data shows LNTH's Return on Capital Employed at 14.85% in Q1 2026, 16.2% in Q4 2025, and 18.79% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Lantheus Holdings | 6.52 Bn | 5.93 Bn | 241.86 Mn | 14.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.78% |
| Mar 31, 2026 | 14.85% |
| Dec 31, 2025 | 16.20% |
| Sep 30, 2025 | 18.79% |
| Jun 30, 2025 | 24.24% |
| Mar 31, 2025 | 25.56% |
| Dec 31, 2024 | 25.75% |
| Sep 30, 2024 | 39.70% |
| Jun 30, 2024 | 28.31% |
| Mar 31, 2024 | 31.96% |
| Dec 31, 2023 | 26.06% |
| Sep 30, 2023 | 4.43% |
| Jun 30, 2023 | 2.43% |
| Mar 31, 2023 | -3.03% |
| Dec 31, 2022 | 3.77% |
| Sep 30, 2022 | 21.07% |
| Jun 30, 2022 | 9.60% |
| Mar 31, 2022 | -2.43% |
| Dec 31, 2021 | -7.95% |
| Sep 30, 2021 | -3.35% |